Kenvue Inc.
KVUE | NYSE
$19.31
-$0.25 (-1.28%)
At close: Oct 30, 2026, 4:00 PM ET
$19.42
+$0.11 (+0.57%)
After-hours:
Oct 30, 2026, 7:45 PM ET
Company Profile
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Key Executives
| Name | Position |
|---|---|
| Kirk L. Perry | Chief Executive Officer & Director |
| Anil Agarwal | Head of Total Rewards |
| Carlton Lawson | Group President of Europe, Middle East & Africa |
| Caroline Tillett | Chief Scientific Officer |
| Heather R. Howlett | Interim CFO & Chief Accounting Officer |
| Jonathan Halvorson | Chief Digital & Marketing Officer |
| Matthew Orlando | General Counsel |
| Meredith Stevens | Chief Operations Officer |
| Michael Wondrasch | Chief Technology & Data Officer |
| Sofya Tsinis | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 04, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
Kenvue Inc.
| Country | United States |
| IPO Date | May 4, 2023 |
| Industry | Household & Personal Products |
| Sector | Consumer Defensive |
| Employees | 21,890 |
| CEO | Kirk L. Perry |
Contact Details
1 Kenvue Way Summit,
New Jersey 07901 United States
Stock Details
| Ticker Symbol | KVUE |
| Exchange | NYSE |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001944048 |
| CUSIP Number | 49177J102 |
| ISIN Number | US49177J1025 |
| SIC Code | 2844 |
Recent News
- 2 days ago / zacks.comKenvue (KVUE) Surpasses Q3 Earnings Estimates
- 3 days ago / wsj.comKenvue Profit, Revenue Rise as Turnaround Efforts Continue
- 3 days ago / businesswire.comKenvue Reports Third Quarter 2026 Results
- 3 days ago / zacks.comKenvue's Q3 Earnings on the Horizon: Key Insights for Investors
- 5 days ago / prnewswire.comKimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes
- 10 days ago / seekingalpha.comKimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raises
- 12 days ago / businesswire.comKenvue to Announce Third Quarter 2026 Results on October 30, 2026
- 20 days ago / wsj.comKimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
- 20 days ago / prnewswire.comKimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
- 25 days ago / 247wallst.comMarket Concentration Is Spooking Wall Street—I'm Buying Kenvue
Add to Watchlist
Select watchlists to add or remove KVUE